Gilead: Q3 Earnings Snapshot

Gilead Sciences (GILD) reported Q3 net income of $2.43B, or $1.94 per share, exceeding analyst expectations of $2.17 per share. Revenue was $8.3B, surpassing forecasts of $7.81B. The company projects a full-year loss of $1.20 to $0.85 per share.

Original reporting
Published Oct 29, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Gilead: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$GILDBullishMed
01

Why it matters

Q3 outperformance versus consensus can support the stock, but the guided full-year loss range can cap upside and shift focus to drivers behind the loss outlook.

02

Market read

This is a direct earnings print with explicit guidance, giving traders a concrete basis to reprice near-term expectations and risk around the full-year outlook.

03

What to watch

Traders may discount the adjusted EPS beat if non-recurring items are material, and will likely scrutinize what drives the guided losses beyond the headline range.

Relevance 9/10Novelty 8/10Timing: reported Q3 results and full-year guidance on the publication date

Background

The piece is an AP-generated earnings snapshot for Gilead’s third quarter, including EPS, revenue, and full-year guidance.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

Gilead reported Q3 net income of $2.43B and adjusted EPS of $2.55, topping analyst estimates, and issued full-year loss guidance.

Expected impact

Likely near-term support from the Q3 beat, tempered by selling or caution as traders focus on the guided full-year loss range.

Evidence & confidence

The article provides both the upside surprise versus consensus (EPS and revenue) and a specific downside full-year EPS loss range, which typically drives mixed reactions.

Market effects

Reinforces near-term demand and pricing resilience signals for HIV and hepatitis C franchises, though guidance suggests ongoing earnings pressure.

Limited, company-specific read-through for US biotech earnings sentiment.

Moderate for global pharma/HIV peers as a read-across on earnings durability and pipeline/guidance expectations.

Counterpoint

The beat may be less durable if the full-year loss guidance reflects structural margin or pipeline uncertainty that the quarter alone does not resolve.

Key entities

  • Gilead Sciences Inc.

    Reported Q3 net income, adjusted EPS, revenue, and provided full-year loss guidance.

  • Zacks Investment Research

    Provided the analyst consensus estimates referenced in the article.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.

$GSKMed

The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

$GILDMed

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Phase 3 trials show elafibranor (Ipsen) and seladelpar (Gilead Sciences) effectively normalize ALP levels in PBC patients. Both drugs were approved in 2024 for inadequate UDCA response. Trials reported significant ALP reduction and normalization rates, with safety profiles similar to placebo.

$GILDMed

Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer

A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.